Volda

This research investigates whether adding gastropexy, a surgical technique of suturing the gastric remnant to the gastrocolic ligament, can reduce gastroesophageal reflux disease (GERD) symptoms and objective signs in patients undergoing laparoscopic sleeve gastrectomy (LSG) for morbid obesity. LSG is a common weight-loss surgery that removes part of the stomach but can increase reflux, possibly due to the stomach moving into the chest area after surgery. The study aims to find out if preventing this movement with gastropexy can lower reflux rates. Participants in this trial will be randomly assigned to one of two groups: sleeve gastrectomy with gastropexy or sleeve gastrectomy without gastropexy. A total of 550 patients planned for primary LSG will be included. The study will monitor and compare reflux outcomes between the groups over several years, with follow-up visits scheduled at six weeks, one year, two years, and five years after surgery. During the study, researchers will assess reflux symptoms, use of acid-reducing medications, and any reoperations due to reflux over a two-year period. Patient-reported outcome questionnaires will be used to capture symptoms, and follow-up evaluations will help determine the effectiveness of gastropexy in preventing reflux after sleeve gastrectomy. Long-term monitoring will continue up to five years to observe lasting effects.

Researchers are studying the effectiveness and potential complications of new immunotherapies used to treat multiple myeloma, plasma cell leukemia, and AL amyloidosis in routine care settings in Norway. The goal is to fill gaps in knowledge, support future clinical trials, and help develop guidelines for monitoring and managing side effects to improve patient survival and quality of life. This observational study focuses on patients receiving these treatments as part of regular medical care. The treatments studied include Teclistamab, Elranatamab, Talquetamab, Idecabtagene vicleucel, and Ciltacabtagene autoleucel. The study tracks how these therapies are used and dosed in real-world settings outside clinical trials. Patients receive these immunotherapies as planned by their healthcare providers, and their treatment details and outcomes are observed over time. Participants will be followed for up to ten years from the start of treatment. Researchers will gather data on overall response rates, progression-free survival, time to next treatment, and overall survival. They will also monitor the frequency and severity of adverse events, infection patterns, antibiotic resistance, and use of antimicrobial prevention methods. Data collection includes real-world clinical outcomes to better understand the long-term effects and safety of these immunotherapies.